SOUČEK, Filip, Naima COVASSIN, Prachi SINGH, Lukáš RŮŽEK, Tomáš KÁRA, Mahmoud SULEIMAN, Amir LERMAN, Celeste KOESTLER, Paul A. FRIEDMAN, Francisco LOPEZ-JIMENEZ a Virend K. SOMERS. Effects of Atorvastatin (80 mg) Therapy on Quantity of Epicardial Adipose Tissue in Patients Undergoing Pulmonary Vein Isolation for Atrial Fibrillation. American Journal of Cardiology. Bridgewater: Excerpta Medica INC-Elsevier Science INC, 2015, roč. 116, č. 9, s. 1443-1446. ISSN 0002-9149. Dostupné z: https://dx.doi.org/10.1016/j.amjcard.2015.07.067.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Effects of Atorvastatin (80 mg) Therapy on Quantity of Epicardial Adipose Tissue in Patients Undergoing Pulmonary Vein Isolation for Atrial Fibrillation
Autoři SOUČEK, Filip (203 Česká republika, garant, domácí), Naima COVASSIN (840 Spojené státy), Prachi SINGH (840 Spojené státy), Lukáš RŮŽEK (203 Česká republika, domácí), Tomáš KÁRA (203 Česká republika, domácí), Mahmoud SULEIMAN (840 Spojené státy), Amir LERMAN (840 Spojené státy), Celeste KOESTLER (840 Spojené státy), Paul A. FRIEDMAN (840 Spojené státy), Francisco LOPEZ-JIMENEZ (840 Spojené státy) a Virend K. SOMERS (840 Spojené státy).
Vydání American Journal of Cardiology, Bridgewater, Excerpta Medica INC-Elsevier Science INC, 2015, 0002-9149.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30201 Cardiac and Cardiovascular systems
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 3.154
Kód RIV RIV/00216224:14110/15:00085409
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1016/j.amjcard.2015.07.067
UT WoS 000364621400021
Klíčová slova anglicky CARDIOVASCULAR RISK; STATINS; HEART; DIFFERENTIATION; METAANALYSIS; CHOLESTEROL; 3T3-L1; TRIALS; CELLS; FAT
Štítky EL OK
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Ing. Mgr. Věra Pospíšilíková, učo 9005. Změněno: 28. 12. 2015 14:02.
Anotace
Epicardial adipose tissue (EAT) has been recognized as a sensitive marker of cardiometabolic risk. Recent evidence suggests efficacy of long-term statin therapy in reducing EAT in patients with coronary artery disease. Whether short-term statin therapy is associated with changes in the volume of EAT is currently unknown. A cohort of patients with atrial fibrillation who underwent pulmonary vein isolation were randomized to receive either 80 mg/day of atorvastatin (n = 38, 32 men, age 56 11 years) or placebo (n = 41, 33 men, age 56 +/- 10 years) for a 3-month period. EAT volume was assessed by cardiac computed tomography at baseline and at follow-up. Patients randomized to statin treatment exhibited a modest but significant decrease in median EAT volume (baseline vs follow-up: 92.3 cm(3) [62.0 to 133.3] vs 86.9 cm(3) [64.1 to 124.8], p < 0.05), whereas median EAT remained unchanged in the placebo group (81.9 cm(3) [55.5 to 110.9] vs 81.3 cm(3) [57.1 to 110.5], p = NS). Changes in median systemic inflammatory markers and lipid profile were also seen with statin treatment: C-reactive protein (2.4 mg/L [0.7 to 3.7] vs 1.1 mg/L [0.5 to 2.7], p < 0.05), total cholesterol (186 mg/dL [162.5 to 201] vs 123 mg/dL [99 to 162.5], p < 0.001), and low-density lipoprotein cholesterol (116 mg/dL [96.5 to 132.5] Vs 56 [40.5 to 81] mg/dL, p < 0.001) diminished, whereas median body mass index did not change (27.8 kg/m(2) [25 to 30] versus 27.6 kg/m(2) [25.7 to 30.5], p = NS). No variations occurred in the placebo group. In conclusion, short-term intensive statin therapy significantly reduced the volume of EAT in patients with atrial fibrillation. (C) 2015 Elsevier Inc. All rights reserved.
VytisknoutZobrazeno: 26. 4. 2024 18:21